Molecular structure of 13,14-Dihydro-prostaglandin E1 (PGE0), CAS Number: 19313-28-1
13,14-Dihydro-prostaglandin E1 (PGE0) (CAS 19313-28-1)
Alternate Names:
13,14-dihydro PGE1
Application:
13,14-Dihydro-prostaglandin E1 (PGE0) is a PGE1 metabolite that inhibits platelet aggregation & shows antimitotic activity
CAS Number:
19313-28-1
Purity:
98%
Molecular Weight:
356.5
Molecular Formula:
C20H36O5
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
13,14-Dihydro-prostaglandin E1 (PGE0) is the hydrogenated circulating metabolite of PGE1 (sc-201223). This compound shows similar vasodilation activity to PGE1, inhibits platelet aggregation, and demonstrates antimitotic activity. It has been shown that this product had an affect on vascular wall lipid metabolism by decreasing low-density lipoprotein influx into the aortic wall.
13,14-Dihydro-prostaglandin E1 (PGE0) (CAS 19313-28-1) References
- 13,14-Dihydro-prostaglandin E1 decreases low-density lipoprotein influx into rabbit aorta. | Sinzinger, H., et al. 1992. Eur J Pharmacol. 219: 129-33. PMID: 1397039
- Synergism between PGE1-metabolites(13,14-dihydro-prostaglandin E1, 15-keto prostaglandin E1, 15-keto-13,14-dihydro-prostaglandin E1) and nitric oxide (NO) on platelet aggregation. | Katzenschlager, R., et al. 1992. Prostaglandins Leukot Essent Fatty Acids. 45: 207-10. PMID: 1589447
- Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man. | Ney, P., et al. 1991. Eicosanoids. 4: 177-84. PMID: 1663381
- 13,14-dihydro-PGE1, an in-vivo metabolite of PGE1, decreases mitotic activity induced by corticosteroid administration. | Fitscha, P., et al. 1991. Eicosanoids. 4: 231-3. PMID: 1789999
- Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease. | Peskar, BA., et al. 1991. Prostaglandins. 41: 225-8. PMID: 1852896
- The induction of cyclooxygenase-2 elicited by endotoxin in endothelial cells and macrophages is inhibited by prostaglandin E1 and 13,14-dihydro prostaglandin E1. | Akarasereenont, P., et al. 1995. Agents Actions Suppl. 45: 59-64. PMID: 7717202
- 13,14-Dihydro-prostaglandin E1 in atherosclerosis. | Pallapies, D. and Peskar, BA. 1993. Semin Thromb Hemost. 19: 144-8. PMID: 8356460
- The effect of pulmonary metabolites of prostaglandins E1, E2 and F2alpha on ADP-induced aggregation of human and rabbit platelets [proceedings]. | Westwick, J. 1976. Br J Pharmacol. 58: 297P-298P. PMID: 974413
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
13,14-Dihydro-prostaglandin E1 (PGE0), 1 mg | sc-201259 | 1 mg | $96.00 | |||
13,14-Dihydro-prostaglandin E1 (PGE0), 10 mg | sc-201259A | 10 mg | $480.00 |